• We now accept HSA and FSA for healthcare related services.
Shop Supplements
Book an Appointment

“Normal” Labs but Hidden Disease. The Truth About Fatty Liver.

What is Fatty Liver?

Fatty liver, also called hepatic steatosis, occurs when excess fat builds up in liver cells. Normally, the liver contains a small amount of fat, but when more than 5–10% of its weight is fat, it is considered fatty liver disease.

There are two main types:

Non-Alcoholic Fatty Liver Disease (NAFLD): Linked to diet, blood sugar regulation, and metabolic health rather than alcohol.

Alcoholic Fatty Liver Disease: Caused by heavy alcohol use.

Several factors can contribute:

  • Poor diet: High intake of processed foods, high fructose corn syrup, sugar, and refined carbohydrates.
  • Alcohol: Even moderate use can accelerate fat buildup.
  • Insulin resistance and type 2 diabetes: Sugar regulation problems funnel fat into the liver.
  • Obesity, especially abdominal obesity: Belly fat strongly increases risk.
  • High cholesterol or triglycerides: Unhealthy lipid balance stresses the liver.
  • Gut health issues: Dysbiosis and leaky gut may trigger inflammation that affects the liver.

Why is Fatty Liver Harmful?

The liver is a central “processing hub” for toxins, hormones, nutrients, and cholesterol. When it becomes overloaded with fat, it struggles to function effectively. Over time, this can lead to:

  • Inflammation, non-alcoholic steatohepatitis (NASH)
  • Scarring (fibrosis), if left untreated without lifestyle modifications long-term, this can lead to liver damage.
  • Cirrhosis, which is advanced, irreversible scarring with risk of liver failure
  • Increased cardiovascular and kidney disease. Fatty liver is linked to diabetes, cognitive decline (dementia) and heart disease.
  • Increased risk of liver cancer or liver failure in advanced stages.

How Doctors Measure Severity

Fatty liver is staged by both the amount of fat and the extent of scarring:

  • Steatosis (fat content):
    • Grade 1: Mild (5–33% of liver cells contain fat)
    • Grade 2: Moderate (34–66%)
    • Grade 3: Severe (>66%)
  • Fibrosis (scarring):
    • F0: No fibrosis
    • F1: Mild scarring around blood vessels
    • F2: Moderate scarring spreading more widely
    • F3: Severe “bridging” fibrosis
    • F4: Cirrhosis, advanced and irreversible

Doctors may also use the NAFLD Activity Score (0–8), which combines fat, inflammation, and cell injury.

How Do You Know if You Have Fatty Liver?

Many people do not notice symptoms until disease progression is advanced. Early clues can include fatigue, vague abdominal discomfort, or elevated liver enzymes on routine bloodwork.

  • Blood tests: ALT, AST, and GGT can suggest liver stress. Even when values fall within the “normal” laboratory range, a slight elevation compared to your personal baseline may signal early liver strain. Current research suggests that the true healthy upper limit for ALT should be lower than what many labs report. You want to aim for closer to 25 U/L for most adults, and 20 U/L or less for African American individuals [Prati et al., 2002]. This means that results often labeled “normal” may still represent early fatty liver changes. Such subtle shifts can be the nudge to take action. Action isn’t extreme! You can make changes in your diet but eating less processed and more whole and plant based foods, exercise consistently (including weight resistance), and consider supportive supplements such as NAC or milk thistle under provider guidance [Mirhashemi et al., 2022; Khoshbaten et al., 2010].
  • Ultrasound: Detects fat deposits.
  • FibroScan (elastography): Measures fat and stiffness (scarring).
  • MRI or CT scan: Offers detailed imaging.
  • Liver biopsy: Rarely needed but remains the gold standard for staging fibrosis.

Tip: Don’t wait until your labs are “out of range.” Even subtle shifts in liver enzymes can be an early warning sign and an opportunity to reverse course.

Lifestyle and Treatment Approaches

Limit or eliminate alcohol:

  • U.S. guidelines define moderate alcohol use as up to one drink per day for women and up to two drinks per day for men, with at least two alcohol-free days per week. One “standard drink” equals 14 grams of pure alcohol (about 5 oz of wine, 12 oz of beer, or 1.5 oz of distilled spirits).
  • However, even this level of drinking can worsen fatty liver. For anyone with fatty liver disease, the safest approach is abstinence or major reduction.
  • Studies show that stopping alcohol for as little as 2–6 months can significantly reduce liver fat, lower enzymes, and decrease inflammation. In some patients, fatty liver changes can be reversed entirely [O’Shea et al., 2010; Rehm et al., 2013].

Dietary changes:

  • Reduce sugar, refined carbohydrates, and processed foods.
  • Emphasize whole foods such as lean protein, vegetables, legumes, and healthy fats like olive oil, avocado, and omega-3s.

Weight management:

Even a 5–10% weight loss can significantly improve liver health.

Excercise:

Both cardio and resistance training help reduce liver fat and improve insulin sensitivity.

Gut support:

  • Prebiotics (food for good bacteria): garlic, onions, leeks, asparagus, artichokes, oats, legumes, green bananas.
  • Probiotics (live beneficial bacteria): yogurt with live cultures, kefir, sauerkraut, kimchi, miso, tempeh, kombucha, or high-quality supplements.
  • Prebiotics feed the probiotics, so a mix of both is ideal.

Supplements (under provider guidance):

Milk thistle, omega-3 fatty acids, vitamin E (in certain patients), and NAC have been studied for liver support.

Advanced and Emerging Support

Some patients may benefit from advanced options, under medical supervision:

  • Peptides: Compounds such as BPC-157 and KPV are being studied for their potential to reduce inflammation and support tissue repair, including along the liver–gut axis.
  • GLP-1 receptor agonists (e.g., semaglutide, tirzepatide): Originally developed for diabetes and weight loss, these medications improve insulin sensitivity, reduce inflammation, and are showing promise in reducing liver fat.
  • Ongoing monitoring: Periodic labs and imaging allow clinicians to track liver health and treatment response.

Key Takeaway

Fatty liver is silent but common, and importantly, reversible. Through nutrition, activity, alcohol reduction (or abstinence), gut support, and targeted therapies, it is possible to reverse damage and restore liver function. For those who need additional support, emerging options like peptides and GLP-1 therapies are expanding the treatment toolkit.

Your liver is a powerhouse. With the right care, it can keep serving you for decades to come.

References

  1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357.
  2. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of non-alcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.
  3. Mayo Clinic. Nonalcoholic fatty liver disease. https://www.mayoclinic.org/diseases-conditions/nonalcoholic-fatty-liver-disease
  4. National Institute on Alcohol Abuse and Alcoholism (NIAAA). Rethinking Drinking: Alcohol and Your Health. https://www.niaaa.nih.gov
  5. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomized, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–690.
  6. Mirhashemi SM, Dadkhahfar S, Dadkhahfar S, et al. Effect of 8 weeks milk thistle powder (silymarin extract) on non-alcoholic fatty liver disease in patients candidates for bariatric surgery. J Family Med Prim Care. 2022;11(5):2221–2227. doi:10.4103/jfmpc.jfmpc_1654_21.
  7. Khoshbaten M, Aliasgarzadeh A, Masnadi K, et al. N-acetylcysteine improves liver function in patients with non-alcoholic fatty liver disease. Hepat Mon. 2010;10(1):12–16. PMC3270338
  8. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum ALT levels. Ann Intern Med. 2002;137(1):1–10.
  9. O’Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Hepatology. 2010;51(1):307–328.
  10. Rehm J, Samokhvalov AV, Shield KD. Alcohol consumption and liver cirrhosis mortality: An updated systematic review and meta-analysis. Alcohol Res. 2013;35(2):118–128.